Commentary on the MID3 Good Practices Paper

During the last 10 years the European Medicines Agency (EMA) organized a number of workshops on modeling and simulation, working towards greater integration of modeling and simulation (M&S) in the development and regulatory assessment of medicines. In the 2011 EMA – European Federation of Pharma...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:CPT Pharmacometrics Syst Pharmacol
Main Authors: Manolis, Efthymios, Brogren, Jacob, Cole, Susan, Hay, Justin L., Nordmark, Anna, Karlsson, Kristin E., Lentz, Frederike, Benda, Norbert, Wangorsch, Gaby, Pons, Gerard, Zhao, Wei, Gigante, Valeria, Serone, Francesca, Standing, Joseph F., Dokoumetzidis, Aris, Vakkilainen, Juha, van den Heuvel, Michiel, Mangas Sanjuan, Victor, Taminiau, Johannes, Kerwash, Essam, Khan, David, Musuamba, Flora Tshinanu, Skottheim Rusten, Ine
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Commentary
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5529732/
https://ncbi.nlm.nih.gov/pubmed/28653481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12223
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares